Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3865-3874

  Omwoyo, Wesley Nyaigoti ^a,b   Ogutu, Bernhards ^c,d   Oloo, Florence ^c,e   Swai, Hulda ^f   Kalombo, Lonji ^f   Melariri, Paula ^f   Mahanga, Geoffrey Maroa ^b   Gathirwa, Jeremiah Waweru ^c,d  

^a MAASAI MARA UNIVERSITY   (Kenya)

^b JARAMOGI OGINGA ODINGA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Kenya)

^c STRATHMORE UNIVERSITY   (Kenya)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e TECHNICAL UNIVERSITY OF KENYA   (Kenya)

^f DSI CSIR Nanotechnology Innovation Centre   (South Africa)

Author keywords

Antimalarial; Double emulsion; Nanomedicine drug delivery system; Nanotechnology

Indexed keywords

ANTIMALARIAL AGENT; DRUG CARRIER; EMULSION; LIPID; NANOPARTICLE; PRIMAQUINE;

ANIMAL; CHEMISTRY; EMULSION; MALARIA; MOUSE; PARASITEMIA; PLASMODIUM BERGHEI;

ANIMALS; ANTIMALARIALS; DRUG CARRIERS; EMULSIONS; LIPIDS; MALARIA; MICE; NANOPARTICLES; PARASITEMIA; PLASMODIUM BERGHEI; PRIMAQUINE;

EID: 84905986563     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S62630     Document Type: Article

References (44)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005;434:214-217.
2. Bloland PB. Drug resistance in malaria. Available from: http://www.who.int/csr/resources/publications/drugresist/malaria.pdf. Accessed July 16, 2014.
3. World Health Organization. Global Plan for Artemisinin Resistance Containment. Geneva: World Health Organization; 2011. Available from: http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf. Accessed April 13, 2014.
4. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336-1345.
5. Fernando SD, Rodrigo C, Rajapakse S. Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs. Asian Pac J Trop Med. 2011;4(4):330-336.
6. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402-415.
7. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351.
8. Kilawa W, Ntoumi F. Malaria, a search agenda for the eradication era. Lancet. 2009;374:1480-1482.
9. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19:115-120.
10. Alving A, Anold J, Hockwald R. Prevention of curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1985;4:301-306.
11. Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm. 2008;347:136-143.
12. Allen T, Cullis P. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822.
13. Peters W, Robinson B, Tovey G, Rossier J, Jefford C. The chemotherapy of rodent malaria. L. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine resistant parasites. Part 3: Observations on 'Fenzan-50F', a difluorinated 3,3 spirocyclopentane 1,2,4trioxane. Ann Trop Med Parasitol. 1993;87:111-123.
14. Malam Y, Loizidou M, Seifalian A. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592-599.
15. Vauthier C, Couvreur P. Nanomedicines: a new approach for the treatment of serious diseases. J Biomed Nanotechnol. 2007;3:223-234.
16. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003;60:21-37.
17. Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci. 2007;96:2547-2565.
18. Semete B, Booysen L, Lemmer Y, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine. 2010;6(5):662-671.
19. Semete B, Booysen LIJ, Kalombo L, et al. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol. 2010;249(2):158-165.
20. Bruce-Chwatt L. Essential Malariology. New York: John Wiley and Sons; 1980:46-59.
21. Povinelli L, Monson TA, Fox BC, Parise ME, Morrisey JM, Vaidya AB. Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis. J Travel Med. 2003;10:353-355.
22. Pirson P, Steiger R, Trouet A. The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochem Pharmacol. 1982;31:3501-3507.
23. Arica B, Ozer AY, Ercan MT, Hincal AA. Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. J Microencapsul. 1995;12:469-485.
24. Ekambaram P, Abdul HS, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2(1):80-102.
25. Shah C, Shah V, Upadhyay U. Solid lipid nanoparticles: a review. Curr Pharm Res. 2011;1(4):351-368.
26. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196.
27. Sjostrom B, Bergenstahl B. Preparation of submicron particles in lecithin-stabilized o/w emulsions. I. Model drug studies of the precipitation of cholesteryl acetate. Int J Pharm. 1992;88:53-62.
28. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm. 1996;43:104-109.
29. Mühlen A, Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie. 1998;53:552-555.
30. Peters W, Portus JH, Robinson BL. The chemotherapy of rodent malaria XXII. The value of drug resistant strains of Plasmodium berghei in screening for schizontocidal activity. Ann Trop Med Parasitol. 1975;69:155-171.
31. Tona L, Mesia K, Ngimbi NP, et al. In-vivo antimalarial activity of Cassia occidentalis, Morinda morindoides and Phyllanthus niruri. Ann Trop Med Parasitol. 2001;95:47-57.
32. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48:223-236.
33. Iscan YY, Hekimoglu S, Kas S, Hincal AA. Formulation and characterization of solid lipid nanoparticles for skin delivery, conference 'lipid and surfactant dispersed systems'. Moscow: Proceedings Book. 1999:163-166.
34. Schwarz C, Freitas C, Mehnert W, Müller RH. Sterilisation and physical stability of drug-free and etomidate-loaded solid lipid nanoparticles. Proc Int Symp Control Release Bioact Mater. 1995;22:766-767.
35. Schwarz C. Feste Lipidnanopartikel: Herstellung, Charakterisierung, Arzneistof nkorporation under freisetzung, Sterilisation und Lyophilisation [doctoral thesis]. Berlin: Free University of Berlin; 1995.
36. Penkler L, Müller RH, Runge SA, Ravelli V. Inventors; Pharmatec International S.R.L., assignee. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. United States patent US6551619 B1. 2003 Apr 22.
37. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
38. Souza LG, Silva EJ, Martins ALL, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm. 2011;79:189-196.
39. Mahato RI. Pharmaceutical Dosage Forms and Drug Delivery. Boca Raton: CRC Press; 2007.
40. Izumikawa S, Yoshioka S, Aso Y, Takeda Y. Preparation of poly(llactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Control Release. 1991;15(2):133-140.
41. Gupta N, Rajera R, Nagpal M, Arora S. Primaquine loaded chitosan nanoparticles for liver targeting. Pharm Nanotechnol. 2013;1:35-43.
42. Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: preparation and characterization. Carbohydr Polym. 2010;81:243-251.
43. Li P, Wang Y, Peng Z, et al. Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohydr Polym. 2011;85:698-704.
44. Mehnert W, Zur Mühlen A, Dingler A, Weyhers H, Müller RH. Solid lipid nanoparticles ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika. II. Mitteilung: Wirkstoff Inkorporation, Freisetzung und Sterilisierbarkeit. Pharm Ind. 1997;59:511-514.